目的:探究抗菌药物对非小细胞肺癌(NSCLC)患者一线含铂化疗预后的影响。方法:回顾性纳入接受一线含铂双药化疗的晚期NSCLC患者125例,化疗期间使用抗菌药物的患者为抗菌药物组,未使用的为对照组。对比化疗2周期后与基线的检查报告,对患者的疗效及不良反应进行评价。临床终点为客观有效率(ORR)和疾病控制率(DCR),不良反应包括血液系统不良反应(白细胞减少、粒细胞减少、血小板减少、血红蛋白减少)和胃肠道不良反应。结果:抗菌药物组的ORR(8.3 %)显著低于对照组ORR(20.8 %)(P=0.045)。抗菌药物组的DCR(77.8 %)低于对照组的DCR(90.6 %),但差异无统计学意义(P=0.059)。两组的血液系统不良反应事件(包括白细胞减少、粒细胞减少、血小板减少、血红蛋白减少)无显著差异(P＞0.05),而胃肠道不良反应率有显著差异(P=0.036),抗生组有50例(69.4 %),对照组有27例(50.9 %)。结论:抗菌药物可影响晚期NSCLC患者一线化疗患者的预后,应在严格适应证的情况下给癌症患者使用。
Objective: To investigate the effect of antibiotics on the prognosis of first-line platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC). Methods: A total of 125 patients with advanced NSCLC who received first-line platinum-based two-drug chemotherapy were retrospectively included, and those who used antibiotics during chemotherapy were the antibiotics group and those who did not were the control group.The efficacy and adverse effects of patients were evaluated by comparing the examination reports after 2 cycles of chemotherapy with those at baseline.Clinical endpoints were objective effectiveness rate (ORR) and disease control rate (DCR), and adverse reactions included hematologic adverse reactions (leukopenia, granulocytopenia, thrombocytopenia, hemoglobin reduction) and gastrointestinal adverse reactions. Results: The ORR in the antibiotics group (8.3 %) was significantly lower than that in the control group (20.8 %) (P=0.045).The DCR in the antibiotics group (77.8 %) was lower than that in the control group (90.6 %), but there was no statistical difference (P=0.059).There was no significant difference in the hematologic adverse events including leukopenia, granulocytopenia, thrombocytopenia, and hemoglobin reduction between the two groups (P＞0.05).In contrast, there was a significant difference in gastrointestinal adverse reactions (P=0.036), with 50 cases (69.4 %) in the antibiotics group and 27 cases (50.9 %) in the control group. Conclusion: Antibiotics can affect the prognosis of patients with advanced NSCLC treated with first-line chemotherapy and should be given to cancer patients under strict indications.
[1] 郑荣寿, 孙可欣, 张思维, 等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2019,(1): 19-28.
[2] Gao Y, Shang Q, Li W, et al. Antibiotics for cancer treatment: a double-edged sword[J].J Cancer.2020,11(17): 5135-5149.
[3] Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity[J].Nat Rev Gastroenterol Hepatol.2017,14(6): 356-365.
[4] Yeung CY, Chiang Chiau JS, Cheng ML, et al. Modulations of probiotics on gut microbiota in a 5-fluorouracil-induced mouse model of mucositis[J].J Gastroenterol Hepatol.2020,35(5): 806-814.
[5] Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J].Science.2013,342(6161): 971-6.
[6] Yue B, Gao R, Wang Z, et al. Microbiota-host-irinotecan axis: a new insight toward irinotecan chemotherapy[J].Front Cell Infect Microbiol.2021,11: 710945.
[7] Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J].Science, 2013,342(6161): 967-970.
[8] Gui QF, Lu HF, Zhang CX, et al. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model[J].Genet Mol Res, 2015,14(2): 5642-5651.
[9] Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J].Science, 2017,357(6356): 1156-1160.
[10] Zhou BL, Xia XY, Wang PQ, et al. Induction and amelioration of methotrexate-induced gastrointestinal toxicity are related to immune response and gut microbiota[J].EBioMedicine, 2018,33: 122-133.
[11] Ahmed J, Kumar A, Parikh K, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors[J].Oncoimmunology, 2018,7(11): e1507670.
[12] Ting NL, Lau HC, Yu J. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes[J].Gut, 2022,71(7):1412-1425.
[13] Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies[J].Microbiome, 2018,6(1): 92.
[14] Cortellini A, Ricciuti B, Facchinetti F, et al. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy[J].Ann Oncol, 2021,32(11): 1391-1399.
[15] Pflug N, Kluth S, Vehreschild JJ, et al. Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota[J].Oncoimmunology, 2016,5(6): e1150399.
[16] Nenclares P, Bhide SA, Sandoval-Insausti H, et al. Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy[J].Eur J Cancer, 2020,131: 9-15.
[17] Wu CS, Lai RX, Li J, et al. Antibiotics modulate chemotherapy efficacy in patients with esophageal cancer[J].Cancer Manag Res, 2020,12:4991-4997.
[18] 武鑫, 赵付雅, 孙加玉, 等. 肠道菌群与肿瘤化疗之间的互作关系[J].中国微生态学杂志, 2021,33(02): 242-245+249.
[19] Ghanem S, Kim CJ, Dutta D, et al. Antimicrobial therapy during cancer treatment: beyond antibacterial effects[J].J Intern Med, 2021,290(1):40-56.
[20] He Y, Fu LH, Li YP, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8+ T cell immunity[J].Cell Metab, 2021,33(5): 988-1000.e7.
[21] Wardill HR, van der Aa SAR, da Silva Ferreira AR, et al. Antibiotic-induced disruption of the microbiome exacerbates chemotherapy-induced diarrhoea and can be mitigated with autologous faecal microbiota transplantation[J].Eur J Cancer, 2021,153: 27-39.
[22] Shen SQ, Lim G, You ZR, et al. Gut microbiota is critical for the induction of chemotherapy-induced pain[J].Nat Neurosci, 2017,20(9): 1213-1216.
